Angiogenesis - Possibilities for therapeutic intervention in rheumatic diseases;Angiogenese - Therapeutische interventionsmöglichkeiten bei rheumatischen erkrankungen

Zeitschrift fur Rheumatologie

Volumn 66, Issue 4, 2007, Pages 304-310

  Maurer, B ^a   Distler, J H W ^b   Moritz, F ^a   Gay, S ^a   Distler, O ^a  

^a UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^b UNIVERSITY HOSPITAL ERLANGEN   (Germany)

Author keywords

Angiogenesis; Mechanisms; Rheumatic diseases; Therapeutic options

Indexed keywords

ANGIOGENIC FACTOR; ATRASENTAN; BEVACIZUMAB; CETUXIMAB; ENDOSTATIN; FIBROBLAST GROWTH FACTOR 2; GEFITINIB; INTERLEUKIN 6; INTERLEUKIN 8; MARIMASTAT; MONOCLONAL ANTIBODY LM 609; PLATELET DERIVED GROWTH FACTOR; SCATTER FACTOR; SORAFENIB; SUNITINIB; TOPOTECAN; TROPONIN; TUMOR NECROSIS FACTOR ALPHA;

ANGIOGENESIS; CARCINOGENESIS; CELL MIGRATION; CELL PROLIFERATION; CLINICAL TRIAL; ENDOTHELIUM CELL; EXTRACELLULAR MATRIX; HUMAN; INFLAMMATION; ISCHEMIA; OVARY CYCLE; PATHOGENESIS; PATHOPHYSIOLOGY; PERICYTE; PHYSIOLOGY; PREGNANCY; REVIEW; RHEUMATIC DISEASE; SMOOTH MUSCLE; VASODILATATION; WOUND HEALING;

EID: 34447330989     PISSN: 03401855     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00393-007-0172-6     Document Type: Review

References (26)

1. Cramer T, Yamanishi Y, Clausen BE et al. (2003) HIF-1alpha is essential for myeloid cell-mediated inflammation. Cell 7: 645-657
2. D'Alessio S, Fibbi G, Cinelli M et al. (2004) Matrix metalloproteinase 12-dependent cleavage of urokinase receptor in systemic sclerosis microvascular endothelial cells results in impaired angiogenesis. Arthritis Rheum 50: 3275-3285
3. Distler JH, Wenger RH, Gassmann M et al. (2004) Physiologic responses to hypoxia and implications for hypoxia-inducible factors in the pathogenesis of rheumatoid arthritis. Arthritis Rheum 50: 10-23
4. Distler O, Del Rosso A, Giacomelli R et al. (2002) Angiogenic and angiostatic factors in systemic sclerosis: increased levels of vascular endothelial growth factor are a feature of the earliest disease stages and are associated with the absence of fingertip ulcers. Arthritis Res 4: R11
5. Distler O, Distler JH, Scheid A et al. (2004) Uncontrolled expression of vascular endothelial growth factor and its receptors leads to insufficient skin angiogenesis in patients with systemic sclerosis. Circ Res 95: 109-116
6. Dor Y, Djonov V, Abramovitch R et al. (2002) Conditional switching of VEGF provides new insights into adult neovascularisation and pro-angiogenic therapy. EMBO J 21: 1939-1947
7. Döme B, Hendrix MJ, Paku S et al. (2007) Alternative vascularization mechanisms in cancer: pathology and therapeutic implications. Am J Pathol 170: 1-15
8. Emanueli C, Madeddu P (2006) Therapeutic angiogenesis: Translating experimental concepts to medically relevant goals. Vascul Pharmacol 45: 334-339
9. Gershwin ME, Abplanalp H, Castles JJ et al. (1981) Characterization of a spontaneous disease of white leghorn chickens resembling progressive systemic sclerosis (scleroderma). J Exp Med 153: 1640-1659
10. Harding J, Burtness B (2005) Cetuximab: an epidermal growth factor receptor chimeric human-murine monoclonal antibody. Drugs Today 41: 107-112
11. Hirata S, Matsubara T, Saura R et al. (1989) Inhibition of in vitro vascular endothelial cell proliferation and in vivo neovascularization by low dose methotrexate. Arthritis Rheum 32: 1065-1073
12. Koch AE, Halloran MM, Haskell CJ et al. (1995) Angiogenesis mediated by soluble forms of E-selectin and vascular cell adhesion molecule-1. Nature 376: 517-519
13. Konttinen YT, Mackiewicz Z, Ruuttila P et al. (2003) Vascular damage and lack of angiogenesis in systemic sclerosis skin. Clin Rheumatol 22: 196-202
14. Lei Y, Haider Hkh, Shujia J, Sim E (2004) Therapeutic angiogenesis. Devising new strategies based on past experiences. Basic Res Cardiol 99: 121-132
15. Majewski S, Skopinska-Rozewska E, Jablonska S et al. (1985) Modulatory effect of sera from scleroderma patients on lymphocyte-induced angiogenesis. Arthritis Rheum 28: 1133-1139
16. Miyasaka N, Hirata Y, Ando K et al. (1992) Increased production of endothelin-1 in patients with inflammatory arthritides. Arthritis Rheum 35: 397-400
17. Nagashima M, Wauke K, Hirano D et al. (2000) Effects of combinations of anti-rheumatic drugs on the production of vascular endothelial growth factor and basic fibroblast growth factor in cultured synoviocytes and patients with rheumatoid arthritis. Rheumatology 39: 1255-1262
18. Neidhart M, Wehrli R, Bruhlmann P et al. (1999) Synovial fluid CD146 (MUC18), a marker for synovial membrane angiogenesis in rheumatoid arthritis. Arthritis Rheum 42: 622-630
19. Norrby K (2006) In vivo models of angiogenesis. J Cell Mol Med 10: 588-612
20. Paleolog EM (2002) Angiogenesis in rheumatoid arthritis. Arthritis Res 4: 81-90
21. Paleolog EM, Young S, Stark AC et al. (1998) Modulation of angiogenic vascular endothelial growth factor (VEGF) by TNFα and IL-1 in rheumatoid arthritis. Arthritis Rheum 41: 1258-1265
22. Salani D, Taraboletti G, Rosano L et al. (2000) Endothelin-1 induces an angiogenic phenotype in cultured endothelial cells and stimulates neovascularisation in vivo. Am J Pathol 157: 1703-1711
23. Shih T, Lindley C (2006) Bevacizumab: an angiogenesis inhibitor for the treatment of solid malignancies. Clin Ther 28: 1779-1802
24. Shimizu K, Oku N (2004) Cancer anti-angiogenic therapy. Biol Pharm Bull 27: 599-605
25. Yamahita A, Yonemitsu Y, Okano S et al. (2002) Fibroblast growth factor-2 determines severity of joint disease in adjuvant-induced arthritis in rats. J Immunol 68: 450-457
26. Ziche M, Donnini S, Morbidelli L (2004) Development of new drugs in aniogenesis. Curr Drug Targets 5: 485-493